Protoaxiom

Protoaxiom is a Sydney-based venture firm investing in early-stage life sciences companies, with a focus on biotech and pharma and therapeutics. The firm engages founders and scientific teams advancing programs in drug discovery, novel modalities, and adjacent therapeutic areas, supporting them through the critical early phases of company building. Its Australian base positions it close to local research institutions and the regional biotech ecosystem while engaging with the global capital and clinical networks typical of biotech development. Limited public information is available in the input about specific portfolio companies and named partners, so this profile reflects the firm’s stated focus and structural characteristics.

Protoaxiom writes checks of $1M to $5M and invests at Pre-Seed, Seed, and Series A stages. Headquartered in Australia, the firm typically engages with companies during formation or early institutional rounds, when scientific direction, team composition, and early IP strategy are still being shaped. Its early-stage focus means it is involved at the most formative points in a biotech’s life, where the choice of platform, indication, and team is most consequential.

For founders and scientific founders, Protoaxiom is most relevant when a biotech or pharma program has rigorous scientific foundations and the team is open to a hands-on partner engaged in the earliest steps of company building. The firm prefers direct conversations about biological mechanism, IP position, and capital plans across long development arcs. Founders should expect detailed scientific diligence, engagement on syndicate construction and clinical strategy, and a partner that understands the realities of advancing Australian-rooted biotech programs into globally competitive clinical development pathways.